Eiger BioPharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EIGRQ research report →
Price Chart
About the company
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical firm dedicated to discovering and advancing treatments for critical health issues, particularly hepatitis delta virus (HDV), among other severe diseases. The company's marketed product, Zokinvy, is prescribed for patients suffering from Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies.
- CEO
- David Apelian
- IPO
- 2014
- Employees
- 25
- HQ
- Palo Alto, CA, US
Get TickerSpark's AI analysis on EIGRQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $12.59M
- P/E
- -0.17
- PEG
- -0.00
- P/S
- 0.80
- P/B
- -0.87
- EV/EBITDA
- -0.41
- Div Yield
- 0.00%
- Gross Margin
- 95.09%
- Op Margin
- -455.12%
- Net Margin
- -475.26%
- ROE
- -367.00%
- ROIC
- -268.20%
Latest fiscal year · YoY change
- Revenue
- $15.77M+17.0%
- Gross Profit
- $15.00M+38.8%
- Op Income
- $-71,786,000
- Net Income
- $-74,963,000+22.5%
- EPS
- $-50.78+27.2%
- OCF Growth
- +10.2%
- FCF Growth
- +10.3%
- 52W High
- $16.00
- 52W Low
- $1.10
- 50D MA
- $11.27
- 200D MA
- $6.94
- Beta
- 2.78
- RSI (14)
- 35
- Avg Volume
- 13.61K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Eiger said it is weeks from Phase 3 HDV data, kept advancing its late-stage pipeline, and reported $4 million of Q3 revenue from Zokinvy.· November 3, 2022
- D-LIVR topline data for Lonafarnib-based HDV regimens is expected in December, with management saying the study is on track and could support NDA filing pathways.
- LIMT-2 for Peginterferon lambda HDV continues site activation and enrollment, with 150 patients planned across 12 countries and 50 sites.
- Avexitide AVANT in congenital hyperinsulinism has been initiated, but no patients have been enrolled yet as site activation and screening preparations continue.
- Zokinvy generated $4 million of US net sales in Q3, and Eiger said 80% of identified US Progeria patients received the drug with 100% payer reimbursement coverage.
- Eiger expects its roughly $121 million cash balance to fund planned operations through 2024, before potential HDV commercialization, and it also has access to up to $35 million more under milestone-linked debt facilities.
Total revenue in Q3 2022 was $4 million, entirely from US Zokinvy net sales, versus $3 million in Q3 2021 and $3.3 million in Q2 2022. Cost of sales was $1.2 million, including a one-time write-off of a nonconforming inventory batch; R&D was $22.2 million; SG&A was $7 million; and net loss was $27.1 million, or $0.62 per share. The company said it ended September 30 with approximately $121 million in cash, cash equivalents and investments, expects that to fund planned operations through 2024 before potential HDV commercialization, and can access up to $35 million of additional nondilutive capital in two milestone-based tranches.
David Cory framed the quarter around multiple late-stage programs and said the company is focused on delivering data, expanding commercialization, and building toward future launches. He was most emphatic about D-LIVR, calling it a landmark study and saying topline results are just weeks away, while also noting continued progress in LIMT-2 and Avexitide. On Peginterferon lambda for COVID-19, he said Eiger remains disappointed by the FDA’s EUA position but still has conviction in the data and is evaluating next steps.
Sri Ryali highlighted that Q3 revenue was $4 million from Zokinvy, with higher sales driven largely by additional units shipped. He broke out operating expenses of $1.2 million cost of sales, $22.2 million R&D, and $7 million SG&A, leading to a net loss of $27.1 million, or $0.62 per share. He said the company had about $121 million in cash, cash equivalents and investments at September 30, expects that to fund planned operations through 2024, and noted access to up to $35 million of additional cash tied to clinical and regulatory milestones.
Analysts focused heavily on D-LIVR, asking whether Phase 2 composite data and baseline viral load differences might affect Phase 3 outcomes; management said Phase 3 baseline characteristics look very similar to Phase 2, including around 30% cirrhotic patients, and they believe the two-log RNA decline endpoint should be achievable across baseline viral loads. They also asked about Ukraine/Russia site impact, and management said they remain more than adequately powered despite lost or at-risk patients. Other questions covered the bulevirtide/Hepcludex situation, LIMT-2 enrollment speed, Delta Cure feedback, and Avexitide timing; management reiterated December data for D-LIVR, faster enrollment potential for LIMT-2, strong interest in the HDV field, and that Avexitide is still in site activation/screening with no enrolled patients yet.
The clearest positive driver is the imminent December readout for D-LIVR, which management believes offers multiple registration paths for two Lonafarnib-based regimens. Eiger also pointed to growing commercial readiness in HDV, a funded balance sheet through 2024, and strong reimbursement progress for Zokinvy in the US and Europe.
The main risks are that D-LIVR is still unblinded and the company has not yet disclosed the topline outcome, so the central catalyst remains binary. Peginterferon lambda for COVID-19 also hit a regulatory setback when FDA would not consider an EUA application, and Avexitide remains early with no patients enrolled yet. Management also acknowledged geopolitical site disruptions and the uncertainty of future HDV commercialization timing and competitive dynamics.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.0%
- Shares Outstanding
- 1.48M
- Float Shares
- 1.23M
of shares held by institutions
1 13F filers
Held by 1 ETFs
Biggest fund positions in EIGRQ by dollar value.
Our EIGRQ coverage
Recent articles, reports, and earnings notes.
No research on EIGRQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EIGRQ report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.